Specifically, the application of antisense oligonucleotides or inhibitors directed against USP7 (such as P5091 and HBX 19818) and SP1 (like mithramycin A) could facilitate the degradation of TRAF1, thereby reducing the severity of IP. The gene discussed is TRAF1; the disease is incontinentia pigmenti.